Liest sich gut.
CRT Capital recently raised the same valuation question, initiating coverage with a "Buy" rating and a $15 target in this 22-page report . Their initial coverage came out on Briefing.com, but no one other than CRT's clients saw this past Friday's reiteration of the above after the stock dropped below its trading range and rattled investors.
http://seekingalpha.com/article/...-no-love-after-uplisting-to-nasdaq--------------------------------------------------
http://seekingalpha.com/article/...aceuticals-could-be-a-multi-baggerSummary
Epinephrine Pre-Filled Syringe is Poised for Market Share - Revenues with high gross margins should start in 2015.
Taper DPI Should Generate a Lot of Revenue - Truly novel delivery device could generate more than $1 billion annually.
APC-1000 is One Trial From the Market - And looking to take share from the fastest growing drug in its class.
We think Adamis Pharmaceuticals (ADMP) is one of the most undervalued stocks in the market. Adamis is bringing three products to market with a high probability of success, and very high upside. The four most important trends and catalysts for Adamis are:
1) Epinephrine Pre-Filled Syringe is Poised for Market Share
A) Injectable Epinephrine is a Large Market - Anaphylaxis is common and deadly, injectable epinephrine is a billion dollar market.
B) Epinephrine is a Growing Market - The prevalence of serious allergies is growing, and the School Access to Emergency Epinephrine Act is a huge catalyst going forward.
C) Adamis' Pre-Filled Syringe Meets a Need in the Market - Adamis' simple and cost-effective solution should get Tier 1 insurance coverage.
-----------
Jeder ist für sein Handeln selbst verantwortlich. Keine Kaufs-/Verkaufsempfehlung !!!
Im Unterschied zur Straßenbahn wird an der Börse zum Ein- und Aussteigen nicht geklingelt.
1 |
2 |
3
Thread abonnieren
